<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The PI3K-mTOR (<z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase-mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> kinase) pathway is activated in the majority of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, and there is interest in assessing whether inhibitors of PI3K or mTOR kinase have efficacy in treating <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we define the effectiveness of specific mTOR (AZD8055) and PI3K (GDC-0941) inhibitors, currently in clinical trials, in treating spontaneous B-cell follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that develops in PTEN(+/-)LKB1(+/hypo) mice </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The PTEN(+/-)LKB1(+/hypo) mice were administered AZD8055 or GDC-0941, and the volumes of B-cell follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were measured by MRI </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> samples were analysed by immunohistochemistry, immunoblot and flow cytometry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The AZD8055 or GDC-0941 induced ∼40% reduction in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> volume within 2 weeks, accompanied by ablation of phosphorylation of AKT, S6K and SGK (serum and <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> protein kinase) protein kinases </plain></SENT>
<SENT sid="5" pm="."><plain>The drugs reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell proliferation, promoted <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and suppressed centroblast population </plain></SENT>
<SENT sid="6" pm="."><plain>The AZD8055 or GDC-0941 treatment beyond 3 weeks caused a moderate additional decrease in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> volume, reaching ∼50% of the initial volume after 6 weeks of treatment </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumours</z:e> grew back at an increased rate and displayed similar high grade and diffuse <z:mp ids='MP_0000002'>morphology</z:mp> as the control untreated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> upon cessation of drug treatment </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: These results define the effects that newly designed and specific mTOR and PI3K inhibitors have on a spontaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> model, which may be more representative than <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> frequently employed to assess effectiveness of kinase inhibitors </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest that mTOR and PI3K inhibitors would benefit treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in which the PI3K pathway is inappropriately activated; however, when administered alone, may not cause complete regression of such <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>